Initiation of highly active antiretroviral therapy at CD4+ T lymphocyte counts of >350 cells/mm3: Disease progression, treatment durability, and drug toxicity

Clinical Infectious Diseases

Volumn 36, Issue 6, 2003, Pages 812-815

  Sterling, Timothy R ^a,b   Chaisson, Richard E ^a,b   Moore, Richard D ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIDE EFFECT; T LYMPHOCYTE; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; MALE; REPRODUCIBILITY OF RESULTS;

EID: 0037444040     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/367934     Document Type: Article

References (13)

1. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA 2001; 286:2568-77.
2. Phillips AN, Staszewski S, Weber R, et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA 2001; 286:2560-7.
3. + T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS 2001; 15:2251-7.
4. 6/L. AIDS 2002; 16:1371-81.
5. + cell counts [abstract 13]. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle). 2002:57.
6. Yeni PG, Hammer SM, Carpenter CC, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel JAMA 2002; 288:222-35.
7. Panel on Clinical Practices for Treatment of HIV Infection, US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents-February 4, 2002. 2002. Available at: http://www.aidsinfo.nih.gov/guidelines/default_db2.asp?id=50. Accessed 24 February 2003.
8. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-30.
9. Fellay J, Boubaker K, Ledergerber B, et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 2001; 358:1322-7.
10. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7.
11. Moore RD, Chaisson RE. Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996; 124:633-42.
12. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41 (RR- 17):1-19.
13. Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS 1999; 13:F35-43.